The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

mgipharma.com

Stage

Acq - P2P | Acquired

Valuation

$0000 

About MGI Pharma

MGI Pharma is an oncology-focused biopharmaceutical company that acquires, develops and commercializes proprietary products that address the unmet needs of cancer patients. MGI Pharma has a portfolio of proprietary pharmaceuticals and intends to become a leader in oncology. MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection, Salagen(R) Tablets (pilocarpine hydrochloride) and Hexalen(R) (altretamine) capsules in the United States. The Company directly markets its products in the U.S. and collaborates with partners in international markets.

MGI Pharma Headquarter Location

5775 West Old Shakopee Road Suite 100

Minneapolis, Minnesota, 55437,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing MGI Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

MGI Pharma is included in 1 Expert Collection, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

MGI Pharma Patents

MGI Pharma has filed 3 patents.

The 3 most popular patent topics include:

  • Blood pressure
  • Cardiovascular physiology
  • Inflation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/11/2021

Blood pressure, Inflation, Cardiovascular physiology, Monetary policy, Systems of units

Application

Application Date

8/11/2021

Grant Date

Title

Related Topics

Blood pressure, Inflation, Cardiovascular physiology, Monetary policy, Systems of units

Status

Application

Latest MGI Pharma News

Helsinn appoints Mary Lynne Hedley to Board of Directors

Apr 29, 2021

April 29, 2021 03:00 ET Lugano/Pazzallo, SWITZERLAND Lugano, Switzerland, April 29, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce the appointment of Dr. Mary Lynne Hedley as a new member of its Board of Directors, effective April 28, 2021. Dr. Hedley is an immunologist and cancer cell biologist, with a vast level of experience within the pharmaceutical industry, specifically within the field of oncology. Most recently, Dr Hedley was Director, President and Chief Operating Officer at TESARO, a biotechnology company she co-founded in 2010, focused on the development and global commercialization of oncology therapeutics. During her time at TESARO the team built up a pipeline of early and late stage drug candidates including the commercial product niraparib, a PARP inhibitor that changed the treatment paradigm for women diagnosed with ovarian cancer. The company was acquired by GlaxoSmithKline in 2019 for $5.1 billion. Prior to founding TESARO, Dr. Hedley was Executive Vice President and CSO of the biotechnology company, Abraxis Bioscience, responsible for R&D, Operations, Medical Affairs and Business Development. Elsewhere she was Executive Vice President of Eisai Inc, with a focus on the global reorganization of its R&D program and building a global oncology strategy. She was also Executive Vice President, as well as CSO, responsible for R&D, at MGI PHARMA (MGI) until its acquisition by Eisai in 2008. In addition, she was Co-Founder, Director, President and CEO of ZYCOS prior to its acquisition by MGI in 2004. Dr. Hedley received her bachelor’s degree in Microbiology from Purdue University and her PhD in Molecular and Cellular Immunology from UT Southwestern Medical Center, USA. Following this, Dr. Hedley carried out her postdoctoral training at Harvard University in the areas of Immunology and Gene Regulation. Dr. Hedley currently sits on the board at Veeva and Centessa Pharmaceuticals and is a board member of the Youville Assisted Living Communities and WITH (Women Innovating Together in Healthcare). Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: “I am delighted to welcome Dr. Hedley to Helsinn’s Board of Directors and look forward to benefitting from her many years of biopharmaceutical industry experience. Helsinn Group is a leading cancer care and rare disease product company and her scientific expertise, as well as her leadership and board level know-how, will be invaluable as we continue to progress and deliver our innovative pipeline of oncology and rare disease products to patients.” Dr. Mary Lynne Hedley, newly appointed member of the Helsinn Board of Directors, commented: “Helsinn is a company that has proved its long-standing commitment to providing patients with first-in-class cancer care, whether that be through supportive care or therapeutics. The team’s dedication to improving patients’ quality of life is something I share, and I am thrilled to be working with Riccardo and the whole Board as we work towards this mission.” About the Helsinn Group Helsinn is a privately-owned Swiss Pharma Company which, since 1976, has been improving the lives of patients, guided by core family values of respect, integrity and quality. The Group has an extensive portfolio of marketed innovative cancer and rare disease therapies, a robust drug development pipeline and ambitions to further accelerate its growth through in-licensing and acquisitions to address unmet medical needs. Helsinn operates a unique integrated licensing business model, achieving success with long-standing partners in 190 countries, who share its values. The Group’s pharmaceutical business (Helsinn Healthcare) is headquartered in Lugano, Switzerland with operating subsidiaries in the U.S. (Helsinn Therapeutics US) and China (Helsinn Pharmaceuticals China) which market the Group’s products directly in these countries. The Group has additional operating subsidiaries in Switzerland (Helsinn Advanced Synthesis, an active pharmaceutical ingredient manufacturer) and Ireland (Helsinn Birex Pharmaceuticals, a drug product manufacturer). 3B Future Health Fund (formerly known as Helsinn Investment Fund) was created to enhance the future of healthcare by providing funding and strategic support to innovative companies. Helsinn Group plays an active and central role in promoting social transformation in favor of people and the environment. Corporate social responsibility is at the heart of everything we do which is reinforced in the company's strategic plan by a commitment to sustainable growth. To learn more about Helsinn Group please visit www.helsinn.com For more information:

  • Where is MGI Pharma's headquarters?

    MGI Pharma's headquarters is located at 5775 West Old Shakopee Road, Minneapolis.

  • What is MGI Pharma's latest funding round?

    MGI Pharma's latest funding round is Acq - P2P.

  • Who are the investors of MGI Pharma?

    Investors of MGI Pharma include U.S. Department of Energy and Walter Robb.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.